new glp-1 weight loss The Access Gap: Mapping Who Can Actually Afford America's Miracle Weight-Loss Drugs How GLP-1 medications are transforming

Akkermansia muciniphila secretes a glucagon-like peptide-1-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice

Wean & Ease does not make a medication safer

The global obesity GLP-1 market size accounted for USD 8.21 billion in 2025 and is predicted to increase from USD 10.12 billion in 2026 to approximately USD 66.57 billion by 2035, expanding at a CAGR of 23.28% from 2026 to 2035

Something not quite right

Tirzepatide: a review in type 2 diabetes

Global, Regional, and National Comparative Risk Assessment of 79 Behavioural, Environmental and Occupational, and Metabolic Risks or Clusters of Risks, 1990-2015: A Systematic Analysis for the Global Burden of Disease Study 2015